Clinical evaluation of a microsample coagulation analyzer, and comparison with existing techniques

Catheterization and Cardiovascular Diagnosis

Volumn 39, Issue 1, 1996, Pages 97-102

  Carter, Andrew J ^a,b   Hicks, Karen ^a   Heldman, Alan W ^a   Resar, Jon R ^a   Laird, John R ^a   Coombs, Vicki J ^a   Brinker, Jeffrey A ^a   Blumenthal, Roger S ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

anticoagulation; heparin; PTCA

Indexed keywords

ANTICOAGULATION; ARTICLE; BLOOD ANALYSIS; BLOOD CLOTTING TIME; BLOOD SAMPLING; BLOOD VOLUME; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; HUMAN; HUMAN CELL; HUMAN TISSUE; PARTIAL THROMBOPLASTIN TIME; REPRODUCIBILITY;

ANTICOAGULANTS; BLOOD COAGULATION TESTS; CORONARY DISEASE; EVALUATION STUDIES; HEPARIN; HUMANS; PARTIAL THROMBOPLASTIN TIME; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; REPRODUCIBILITY OF RESULTS; ROC CURVE;

EID: 0029789074     PISSN: 00986569     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0304(199609)39:1<97::AID-CCD22>3.0.CO;2-K     Document Type: Article

References (13)

1. Lincoff AM, Topol EJ: Abrupt vessel closure. In Topol EJ (ed): "Textbook of Interventional Cardiology." Philadelphia: W.B. Saunders, 1994, pp 207-230.
2. Satler LF, Leon MB, Kent KM, Pichard AD: Strategies for acute occlusion after coronary angioplasty. J Am Coll Cardiol 19:936-938, 1992.
3. Blumenthal RS, Wolff MR, Resar JR, Coombs VJ, Brinker JA: Preprocedural anticoagulation does not reduce angioplasty heparin requirements. Am Heart J 125:1221-1225, 1993.
4. Ferguson JJ, Dougherty KG, Gaos CM, Bush HS, Marsh KC, Leachman DR: Relation between procedural activated coagulation time and outcome after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 23:1061-1065, 1994.
5. Narins CR, Hillegass WB, Nelson CL, Tcheng JE, Harrington RA, Phillips HR, Stack RS, Califf RM: Relation between activated clotting during angioplasty and abrupt closure. Circulation 93:667-671, 1996.
6. Hillegass WB, Narins CR, Brott BC, Haura EB, Phillips HR, Stack RS, Califf RM: Activated clotting time predicts bleeding complications from angioplasty (abstract). J Am Coll Cardiol 184, 1994.
7. Blumenthal RS, Carter AJ, Resar JR, Coombs V, Gloth ST, Dalal J, Brinker JA: Comparison of bedside and hospital laboratory coagulation studies during and after coronary intervention. Cathet Cardiovasc Diagn 35:9-17, 1995.
8. Ogilby JD, Kopelman HA, Klein LW, Agarwal JB: Adequate heparinization during PTCA: Assessment using activated clotting times. Cathet Cardiovasc Diagn 18:206-209, 1989.
9. Avendano A, Ferguson JJ: Comparison of Hemochron and Hemotec activated coagulation time target values during percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 23: 907-910, 1994.
10. Altman DG, Bland JM: Measurement in medicine: The analysis of method comparison studies. Statistician 32:307-317, 1983.
11. Hanley JA, McNeil BJ: The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 142: 29-36, 1982.
12. Hanley JA, McNeil BJ: A method of comparing the areas under receiver operating characteristics curves derived from the same cases. Radiology 148:839-843, 1983.
13. Reiner JS, Coyne KS, Lundergan CF, Ross AM: Bedside monitoring of heparin therapy: Comparison of the activated clotting time to the activated partial thromboplastin time. Cathet Cardiovasc Diagn 32:49-52, 1994.